Abstract
1. A single centre, prospective, randomized, triple-blind, controlled, parallel-group trial compared the effectiveness and safety of two sclerosing agents, 0.2% polidocanol plus 70% hypertonic glucose (HG) vs 75% HG alone, to treat telangiectasias in the lower limbs of 115 patients, 98 of whom completed the study. The primary effectiveness endpoint was elimination of 75% of the telangiectasias within 60 days vs. the pre-treatment pattern. How much was the percentage of reduction of telangiectasias with 0.2% polidocanol plus 70% HG?1A)77%B)82%C)88%D)91%E)97%
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
